ArticleEuropean journal of nuclear medicine and molecular imaging2019
Amyloid imaging for differential diagnosis of dementia: incremental value compared to clinical diagnosis and [
Article in European journal of nuclear medicine and molecular imaging, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 30 citations in OpenAlex.
- Use of Amyloid Positron-Emission Tomography to Diagnose Alzheimer's Disease in Clinical Practice in South Korea: Expert Recommendations.Journal of clinical neurology (Seoul, Korea) · 2025Review
- [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Article
- Astragaloside IV Improves Cognitive Impairment by Reducing β-Amyloid and Tau Protein Deposition in Hippocampal Tissue of db/db Mice: A PET/CT Imaging-Based Study.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Article
- [Temporobasal meningioma as possible cause of a cognitive disturbance with depression in old age].Der Nervenarzt · 2025Article
- Incremental value of amyloid PET in a tertiary memory clinic setting in China.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- The use of neuroimaging techniques in the early and differential diagnosis of dementia.Molecular psychiatry · 2023Review
- Frontotemporal Dementia, Where Do We Stand? A Narrative Review.International journal of molecular sciences · 2023Review
- PET molecular imaging for pathophysiological visualization in Alzheimer's disease.European journal of nuclear medicine and molecular imaging · 2023Review
- Multimodality imaging of neurodegenerative disorders with a focus on multiparametric magnetic resonance and molecular imaging.Insights into imaging · 2023Review
- Brain Amyloid in Sporadic Young Onset Alzheimer's Disease.Journal of Alzheimer's disease reports · 2023Article
- Updates in the Impact of Chronic Systemic Inflammation on Vascular Inflammation by Positron Emission Tomography (PET).Current cardiology reports · 2022Review
- Development of Amyloid PET Analysis Pipeline Using Deep Learning-Based Brain MRI Segmentation-A Comparative Validation Study.Diagnostics (Basel, Switzerland) · 2022Article
- Machine learning methods to predict amyloid positivity using domain scores from cognitive tests.Scientific reports · 2021Article
- Clinical impact ofEuropean journal of nuclear medicine and molecular imaging · 2021Article
- Differential diagnosis of parkinsonism: a head-to-head comparison of FDG PET and MIBG scintigraphy.NPJ Parkinson's disease · 2020Article
- Initial Physician Experience with [Journal of Alzheimer's disease reports · 2020Article
- Cerebral Small Vessel Disease and Alzheimer's Disease: A Review.Frontiers in neurology · 2020 · on this mapReview
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeCerebral beta-amyloid and regional glucose metabolism assessed by positron emission tomography (PET) are used as diagnostic biomarkers for Alzheimer's disease (AD). The present study validates the incremental diagnostic value of amyloid PET in addition to clinical diagnosis and [
methodsOf 138 consecutive patients with cognitive impairment who received combined [
resultsAfter disclosure of the amyloid PET results, clinical and [
conclusionAmyloid PET provides significant incremental diagnostic value beyond clinical and [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.